...
首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia.
【24h】

TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia.

机译:急性淋巴细胞白血病患者输注骨髓细胞后的TRALI。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: TRALI is one of the most serious, life-threatening complications after blood transfusion. Antibodies against neutrophils or HLA molecules from the donor are thought to be the primary causative agents. Rarely, antibodies in the recipient may react with transfused neutrophils and initiate the same events, which raises the possibility that TRALI may also occur in an allogeneic PBPC transplantation setting. CASE REPORT: A 30-year-old Japanese man with acute lymphoblastic leukemia developed TRALI immediately after the infusion of marrow cells from an unrelated donor. The infusion was suspended, and he gradually improved after receiving steroids and oxygen support. The next day, the remaining cells, which were separated to MNCs, were infused with no reactions. He then recovered over 5 days without the use of mechanical ventilation. RESULTS: Laboratory evaluation disclosed the presence of antibodies to neutrophils in his sera sampled after transplantation, but not in the donor's marrow graft. Hence, antibodies to neutrophils in the recipient may have reacted with neutrophils in the graft and contributed to the development of TRALI. CONCLUSION: This is the first reported case of TRALI after allogeneic BMT. TRALI should be recognized as a rare but serious complication in allogeneic hematopoietic stem cell transplantation.
机译:背景:TRALI是输血后最严重,威胁生命的并发症之一。来自供体的针对中性粒细胞或HLA分子的抗体被认为是主要的病原体。受体中的抗体很少会与输注的中性粒细胞反应并引发相同事件,这增加了TRALI也可能发生在同种异体PBPC移植中的可能性。病例报告:一名30岁的日本急性淋巴细胞白血病患者在从无关的供体中注入骨髓细胞后立即发生了TRALI。输液暂停,接受类固醇和氧气支持后他逐渐好转。第二天,将剩下的细胞分离成MNC,不进行任何反应。然后,他在不使用机械通气的情况下恢复了5天。结果:实验室评估显示,移植后的血清中存在中性粒细胞抗体,而供体的骨髓移植中没有。因此,受体中嗜中性粒细胞的抗体可能已与移植物中的嗜中性粒细胞反应,并促进了TRALI的发展。结论:这是异基因BMT后首次报道的TRALI病例。在同种异体造血干细胞移植中,TRALI应该被认为是一种罕见但严重的并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号